BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Innovations for Substance Use Disorders - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://i4sud.com
X-WR-CALDESC:Events for Innovations for Substance Use Disorders
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T120000
DTEND;TZID=America/Los_Angeles:20260512T130000
DTSTAMP:20260525T060509
CREATED:20260427T161711Z
LAST-MODIFIED:20260507T105609Z
UID:3634-1778587200-1778590800@i4sud.com
SUMMARY:From Discovery to Impact: Advancing Therapeutics for Substance Use Disorders
DESCRIPTION:Talk Description \nThis presentation will outline the mission\, structure\, and impact of the Division of Therapeutics and Medical Consequences (DTMC)\, established in response to a 1989 Congressional mandate to advance medication development for substance use disorders (SUDs). It will describe how DTMC\, modeled after a virtual pharmaceutical company\, supports all phases of therapeutic development—from discovery through regulatory approval—to improve the management of SUDs and their medical consequences\, including HIV. The presentation will highlight DTMC’s strategic focus on developing safe and effective medications\, biologics\, devices\, digital therapeutics\, and behavioral therapies; its collaborations with industry and federal partners; its regulatory engagement with the FDA; and its record of notable contributions to advancing the treatment for opioid\, stimulant\, cannabis\, and nicotine use disorders. The presentation will include opportunities for collaborations with DTMC and funding opportunities to conduct research in this therapeutic development for SUDs. \nDavid White\, Ph.D. \nDr. David White is the Associate Director of the Division of Therapeutics and Medical Consequences (DTMC) and Chief of the Medications Discovery and Toxicology Branch at the National Institute on Drug Abuse (NIDA). In these roles\, he oversees DTMC’s preclinical medication discovery and safety assessment efforts for novel pharmacological treatments for substance use disorders. He also coordinates DTMC’s medications development contract program\, serves as the Division’s pharmaceutical liaison\, and leads DTMC’s business development activities. \nDr. White brings more than two decades of leadership experience at NIDA\, including service as Director of the Addiction Treatment Discovery Program from 2009 to 2023. Prior to joining NIDA in 2006\, he conducted substance use disorder–related research as a research faculty member and postdoctoral fellow in the Department of Pharmacology at Emory University School of Medicine\, where he authored numerous peer-reviewed publications. He earned a Ph.D. in neuropharmacology from West Virginia University School of Medicine in 1999 and a B.A. in biology from West Virginia University in 1994.
URL:https://i4sud.com/event/from-discovery-to-impact-advancing-therapeutics-for-substance-use-disorders/
END:VEVENT
END:VCALENDAR